Subcutaneous Amifostine Safety Study
Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized skin rash, and injection-site skin reactions.
Head and Neck Cancer|Lung Cancer|Lymphoma
DRUG: Amifostine administered subcutaneously
Incidence of nausea/vomiting|Incidence of hypotension|Incidence of generalized skin rash|Incidence of injection-site skin toxicity
Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized skin rash, and injection-site skin reactions.